Showing items 1 - 3 of 3

Your selections:

Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study

- Shapiro, Jeremy D., Thavaneswaran, Subotheni, Tebbutt, Niall C., Price, Timothy J., Khasraw, Mustafa, Van Hazel, Guy A., Waring, Paul M., Tejpar, Sabine, Simes, John, Gebski, Val J., Desai, Jayesh, Segelov, Eva, Underhill, Craig R., Robledo, Kristy P., Karapetis, Chistos S., Day, Fiona L., Nott, Louise M., Jefford, Michael, Chantrill, Lorraine A., Pavlakis, Nick

Current opinion on optimal treatment for colorectal cancer

- Price, Timothy J., Segelov, Eva, Shapiro, Jeremy D., Burge, Matthew, Haller, Daniel G., Ackland, Stephen P., Tebbutt, Niall C., Karapetis, Christos S., Pavlakis, Nick, Sobrero, Alberto F., Cunningham, David

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

- Tebbutt, Niall C., Wilson, Kate, Forgeson, Garry, Cunningham, David, Saunders, Mark P., Stockler, Martin R., Chua, Yujo, Zalcberg, John R., Simes, R. John, Price, Timothy J., Gebski, Val J., Cummins, Michelle M., Zannino, Dianna, van Hazel, Guy A., Robinson, Bridget, Broad, Adam, Ganju, Vinod, Ackland, Stephen P.

  • 1
  • Disclaimer
  • Privacy
  • Copyright
  • Contact
  • Deposit